Superworth

Kymera Therapeutics price to sales ratio KYMR

Market value divided by revenue over the last twelve months, since 2021.

Today, Nov 2, 2026
101×
5-year median
34.4×
Against its 5-year history
86th
percentile: 0 is its lowest day, 100 its highest
5-year range
11.8× to 191×
Peer median
7.7×

Kymera Therapeutics' price to sales ratio is 101× as of Nov 2, 2026.

That is above its 5-year median of 34.4×, higher than on 86% of days in the last 5 years.

Over that time it ranged from 11.8× in Oct 2023 to 191× in Jul 2026.

The median for 10 biotech stocks of a similar size is 7.7×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far101×83.0×191×
2025134×27.2×148×
202429.7×23.1×45.7×
202330.2×11.8×44.3×
202229.8×12.0×40.6×
202146.4×38.8×52.7×

Against its peers

Companies in Biotechnology nearest Kymera Therapeutics' size, closest first, today.

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Kymera Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.